Autolus Therapeutics (AUTL) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
14 Sep, 2026Company overview and business model
Commercial-stage biopharmaceutical company focused on next-generation T cell therapies for cancer and autoimmune diseases, leveraging proprietary T cell programming technologies.
Lead product AUCATZYL (obe-cel) approved by FDA in November 2024 for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL); commercial launches in the US (Jan 2025) and UK (Jan 2026).
Obe-cel is also in development for pediatric B-ALL, B-NHL, and autoimmune indications, with ongoing clinical trials and promising early data.
Manufacturing centralized at the Nucleus facility in Stevenage, UK, with Cardinal Health as US distribution partner.
Financial performance and metrics
Financial statements for the year ended December 31, 2025, audited by Ernst & Young LLP, are incorporated by reference.
Company voluntarily files detailed periodic reports on US domestic issuer forms, providing extensive financial disclosures.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of ADSs by the selling securityholder; proceeds from warrant exercise ($1.9314 per ADS) will be received if exercised for cash.
Registration costs borne by the company; selling securityholder pays underwriting fees, commissions, and certain legal expenses.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026